摘要
目的:探讨先天性角化不良基因1(dyskeratosis congenita 1,DKC1)在肝细胞癌(HCC)中的表达及预后意义。方法:运用Oncomine、GEPIA分析DKC1在HCC组织中的表达情况,通过GEPIA分析DKC1与HCC患者生存期的相关性,利用STRING工具分析DKC1的蛋白相互作用网络。结果:Oncomine数据库中DKC1基因癌组织/正常组织表达量分析结果共有421项研究,在癌组织中显著高表达48项,低表达0项。其中有2项研究结果涉及DKC1在HCC与正常肝脏组织中的表达。与对照组相比HCC组织中DKC1 mRNA表达显著高于肝脏正常组织(P<0.05);利用GEPIA数据库生存分析功能发现,DKC1高表达与HCC预后呈负相关(P<0.05);通过STRING数据库构建蛋白互助网络图显示DKC1与NHP2、GAR1、NOP10、NOP56、NOP58、MPHOSPH10、NHP2L1、FBL、TERT、SHQ1等蛋白具有明显相互作用。结论:DKC1基因在HCC组织中高表达,DKC1表达与HCC患者预后相关,高表达患者预后差。
Objective:To investigate the expression and clinical significance of dyskeratosis congenita 1(DKC1)in hepatocellular carcinoma(HCC).Methods:Oncomine and GEPIA databases were used to analyze the expression of DKC1 in HCC tissues.We also used GEPIA to evaluate the correlation between UBE2S and survival.Besides,STRING database was used to explore the protein-protein interaction network of DKC1.Results:The expression of DKC1 gene in tumorous and normal tissues in Oncomine database was analyzed in 421 cases and there were 48 cases with high expression and 0 case with low expression in cancer tissues.Among them,2 studies involved the expression of DKC1 in HCC tissues and normal tissues.Compared with the control group,the expression of DKC1 mRNA in HCC tissues was significantly higher than that in normal liver tissues(P<0.05).Using the survival analysis function of the GEPIA database,it was found that the high expression of DKC1 was negatively correlated with the prognosis of HCC(P<0.05).Besides,analysis of protein interaction network revealed thatproteins,such as NHP2,GAR1,NOP10,NOP56,NOP58,MPHOSPH10,NHP2L1,FBL,TERT,and SHQ1 significantly interacted with DKC1.Conclusion:DKC1 gene is highly expressed in HCC tissue,and the prognosis of patients with high expression of DKC1 is poor.
作者
徐小尚
王胜
章龙珍
XU Xiaoshang;WANG Sheng;ZHANG Longzhen(Department of Oncology,Suqian Hospital Affiliated of Xuzhou Medical University,Suqian Hospital of Nanjing Drum Tower Hospital Group,Jiangsu Suqian 223800,China;Department of Radiation Oncology,the Affiliated Hospital of Xuzhou Medical University,Jiangsu Xuzhou 221002,China)
出处
《现代肿瘤医学》
CAS
北大核心
2022年第12期2210-2213,共4页
Journal of Modern Oncology